Hyporesponsiveness of SPRET/Ei mice to lethal shock induced by tumor necrosis factor and implications for a TNF-based antitumor therapy.
about
Forward genetic analysis of Toll-like receptor responses in wild-derived mice reveals a novel antiinflammatory role for IRAK1BP1A mutation in Irak2c identifies IRAK-2 as a central component of the TLR regulatory network of wild-derived miceIRAK-2 regulates IL-1-mediated pathogenic Th17 cell development in helminthic infection.Sequence divergence of Mus spretus and Mus musculus across a skin cancer susceptibility locus.Mapping segmental and sequence variations among laboratory mice using BAC array CGH.Increased glucocorticoid receptor expression and activity mediate the LPS resistance of SPRET/EI mice.Glucocorticoid-induced microRNA-511 protects against TNF by down-regulating TNFR1.Interspecific recombinant congenic strains between C57BL/6 and mice of the Mus spretus species: a powerful tool to dissect genetic control of complex traits.Balance between short and long isoforms of cFLIP regulates Fas-mediated apoptosis in vivoDetermining differentially expressed miRNAs and validating miRNA--target relationships using the SPRET/Ei mouse strain.Meeting report of the European mouse complex genetics network SYSGENET.Strain- and time-dependent alterations in hepatic iron metabolism in a murine model of nonalcoholic steatohepatitis.
P2860
Q27485589-2288ED9A-24F6-4FA2-9FE1-B67A27D33B06Q27488977-A53AA692-9301-4DC3-988C-0E63000138CAQ31036486-B1D08BD5-53C1-4571-BFDF-C14D303AF661Q33395513-E0166D5C-FF7F-41F3-AC96-38BC53AEC1DFQ33780885-164EAFD5-5E7B-489E-AF90-C1A82724E66EQ34155493-38ED77CF-D0F6-4041-A7DA-2D4A1A25EB18Q36000791-699BE15F-127A-4CCC-A7B3-A7EA1AA4910DQ36416239-3871D9A8-186D-45BC-A278-0F76A7592FFEQ36598979-9AC75EBE-0850-430E-A8A3-B640C3DDDEC1Q41710131-AC2DC56A-C86F-45E1-B972-E516605DF142Q42599213-224C364C-83AC-4CB6-88C1-EFE48F9D88EDQ48017319-06910DD9-E25B-4468-8D2E-C2F411FE7BFF
P2860
Hyporesponsiveness of SPRET/Ei mice to lethal shock induced by tumor necrosis factor and implications for a TNF-based antitumor therapy.
description
2002 nî lūn-bûn
@nan
2002 թուականի Յունիսին հրատարակուած գիտական յօդուած
@hyw
2002 թվականի հունիսին հրատարակված գիտական հոդված
@hy
2002年の論文
@ja
2002年論文
@yue
2002年論文
@zh-hant
2002年論文
@zh-hk
2002年論文
@zh-mo
2002年論文
@zh-tw
2002年论文
@wuu
name
Hyporesponsiveness of SPRET/Ei ...... a TNF-based antitumor therapy.
@ast
Hyporesponsiveness of SPRET/Ei ...... a TNF-based antitumor therapy.
@en
Hyporesponsiveness of SPRET/Ei ...... a TNF-based antitumor therapy.
@nl
type
label
Hyporesponsiveness of SPRET/Ei ...... a TNF-based antitumor therapy.
@ast
Hyporesponsiveness of SPRET/Ei ...... a TNF-based antitumor therapy.
@en
Hyporesponsiveness of SPRET/Ei ...... a TNF-based antitumor therapy.
@nl
prefLabel
Hyporesponsiveness of SPRET/Ei ...... a TNF-based antitumor therapy.
@ast
Hyporesponsiveness of SPRET/Ei ...... a TNF-based antitumor therapy.
@en
Hyporesponsiveness of SPRET/Ei ...... a TNF-based antitumor therapy.
@nl
P2093
P2860
P356
P1476
Hyporesponsiveness of SPRET/Ei ...... a TNF-based antitumor therapy.
@en
P2093
Claude Libert
Frans Van Roy
Jan Staelens
Jean-Louis Guénet
Leen Puimège
P2860
P304
P356
10.1073/PNAS.142293699
P407
P50
P577
2002-06-27T00:00:00Z